6856-31-1
Chemical Structure
Pridinol mesylate
- CAS No.: 6856-31-1
- Formula:C21H29NO4S
- Molecular Weight:391.52
IUPAC Name: 1,1-diphenyl-3-(piperidin-1-yl)propan-1-ol methanesulfonate
InChIKey: VNJHUUNVDMYCRH-UHFFFAOYSA-N
SMILES: CS(=O)(O)=O.OC(C1=CC=CC=C1)(C2=CC=CC=C2)CCN3CCCCC3
Biological Activity: Pridinol mesylate is an orally active, blood-brain permeable, muscarinic acetylcholine receptor (mAChR)-directed muscle relaxant. Pridinol mesylate reduces the conduction of impulses to spinal motor neurons and exerts muscle relaxant activity. Pridinol mesylate inhibits skeletal muscle contractures in diseases of both central and peripheral origin and can be used in research in the field of musculoskeletal diseases[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pridinol mesylate | 99.97% | Pridinol mesylate is an orally active, blood-brain permeable, muscarinic acetylcholine receptor (mAChR)-directed muscle relaxant. Pridinol mesylate reduces the conduction of impulses to spinal motor neurons and exerts muscle relaxant activity. Pridinol mesylate inhibits skeletal muscle contractures in diseases of both central and peripheral origin and can be used in research in the field of musculoskeletal diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pridinol mesylate (Standard) | ≥98% | Pridinol mesylate (Standard) is the analytical standard of Pridinol mesylate (HY-B1343). This product is intended for research and analytical applications. Pridinol mesylate is an orally active, blood-brain permeable, muscarinic acetylcholine receptor (mAChR)-directed muscle relaxant. Pridinol mesylate reduces the conduction of impulses to spinal motor neurons and exerts muscle relaxant activity. Pridinol mesylate inhibits skeletal muscle contractures in diseases of both central and peripheral origin and can be used in research in the field of musculoskeletal diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Richter M, et al. Pharmacokinetics of oral pridinol: Results of a randomized, crossover bioequivalence trial in healthy subjects. Int J Clin Pharmacol Ther. 2021 Jun;59 (6) :471-477. [Content Brief]
- [2]. Lauricella L, et al. Effectiveness rehabilitative therapy and Pridinol Mesylate in low back pain. Front Med (Lausanne) . 2025 Jan 22;11:1470996. [Content Brief]
